What is the difference between SDMA and cystatin C?

Both are early kidney markers that rise before creatinine and are independent of muscle mass. SDMA (0–14 µg/dL) has the stronger evidence base and is the IRIS staging standard; cystatin C (~0.5–1.2 mg/L dog, 0.6–1.8 mg/L cat) is an independent confirmatory marker whose reference interval is assay-dependent.

Is the 14 µg/dL SDMA cut-off reliable?

It is the IDEXX reference upper limit, but independent work (McKenna 2020) found 14 µg/dL produced false positives in about 50% of non-azotemic dogs, and that 18 µg/dL was more accurate (90% sensitivity, 83% specificity). This is why a persistent elevation — not one reading — should drive a CKD diagnosis.

What is the normal SDMA range for cats and dogs?

The IDEXX reference interval is 0–14 µg/dL for both. A persistent value above 14 µg/dL with a normal creatinine supports Stage 1 CKD, but borderline 15–17 µg/dL results should be rechecked rather than treated as definitive.

How much does early kidney screening help a clinic?

Early CKD caught at Stage 1 is managed with diet, blood-pressure control and monitoring — inexpensive, high-compliance care. The screening itself is a billable panel, and the patient becomes a long-term monitoring relationship rather than a late-stage emergency.

Kidney Disease Tests for Dogs and Cats: SDMA and Cystatin C

Q: Why does creatinine miss early kidney disease?

Creatinine only rises after roughly 60–75% of kidney function is lost, and it is affected by muscle mass. SDMA and cystatin C both rise at only 25–40% loss and ignore muscle mass, so they catch decline a year or more earlier.

Q: Can cystatin C replace creatinine?

Not as a standalone. Its reference interval is assay-dependent and it can be shifted by thyroid disease, steroids and inflammation. It works best as an independent confirmatory marker alongside SDMA rather than a replacement.

TL;DR — Creatinine is a late, muscle-mass-dependent marker: it doesn’t move until ~60–75% of kidney function is gone. SDMA and cystatin C both catch decline at ~25–40% loss, often a year or more earlier. SDMA (0–14 µg/dL) is the IRIS staging standard; cystatin C is a useful independent second opinion. The part most guides skip: the widely used 14 µg/dL SDMA cut-off produced false positives in about half of non-azotemic dogs in independent testing, and 18 µg/dL was more accurate. For a clinic, that translates to a simple, billable senior-screening panel that converts a late-stage emergency into a managed, long-term patient.

Chronic kidney disease (CKD) is one of the most common diagnoses in aging cats and dogs — and one of the most commonly missed until it’s advanced. The reason isn’t that the disease is subtle. It’s that the test everyone has relied on for decades shows up late to the party. This guide is for the people who need the early answer: the owner with a senior cat drinking more than usual, and the clinic deciding whether a kidney screening panel is worth adding to the senior workup.

In Plain Terms

Think of the kidney as a filter and creatinine as a water-level gauge. The gauge only reads “danger” when the tank is nearly full — by the time creatinine rises, most of the filter’s capacity is already gone. SDMA and cystatin C are flow meters instead: they register the rate slowing the moment filtration drops, at 25–40% loss instead of 60–75%. That’s the difference between catching a clog early and discovering it after the flood.

For a cat or dog, that difference is measured in years of earlier intervention — a renal diet, blood-pressure control and monitoring started at Stage 1 instead of a crash admission at Stage 3 or 4.

The Creatinine Problem, Restated

Creatinine is cheap, familiar and on every chemistry panel — which is exactly why it has quietly cost so many early diagnoses.

It’s late. Creatinine doesn’t budge until roughly 60–75% of nephron function is gone. By the time it’s high, the kidney is most of the way to failure.
It’s muscle-mass dependent. A wasted geriatric cat produces less creatinine, so a failing kidney can hide behind a “normal” creatinine. The thinner and sicker the patient, the less the marker can be trusted.

The result: too many CKD cases present at Stage 3 or 4, when the intervention window has narrowed to palliation. SDMA and cystatin C are the two markers built to fix this.

What Is SDMA?

Symmetric dimethylarginine (SDMA) is a methylated amino acid produced at a constant rate by all nucleated cells and cleared almost entirely by glomerular filtration, with no meaningful reabsorption or secretion — which is what makes it a near-ideal GFR marker.

Property	SDMA
Reference interval (dog & cat)	0–14 µg/dL
Borderline (persistent)	15–18 µg/dL
Rises at	~25–40% function loss
Muscle-mass dependent?	No

Two things make SDMA genuinely different from creatinine: it rises a year or more earlier, and a wasted senior cat and a muscular young dog with the same kidney function will read the same number. A persistent SDMA above 14 µg/dL with a normal creatinine supports Stage 1 CKD — the earliest, most treatable stage.

The Cut-Off Debate Nobody Advertises

Here’s the part most product pages won’t tell you, because it complicates the marketing story.

The 14 µg/dL upper limit is the IDEXX reference interval, and it’s the number most clinicians memorise. But independent validation found it’s not as clean as the standard suggests. In McKenna et al. (2020), a 14 µg/dL cut-off produced false positives in about 50% of non-azotemic dogs — that is, half the dogs flagged as “early kidney disease” at 14 µg/dL had no measurable GFR decline. Raising the cut-off to 18 µg/dL gave a much better balance: roughly 90% sensitivity and 83% specificity.

What this means in practice, in plain language:

One SDMA of 15–17 µg/dL is not a diagnosis. It’s a flag to recheck. The trend across serial measurements is the diagnosis, not any single value.
A persistent, climbing SDMA is far more meaningful than a one-off borderline result.
This is precisely why cystatin C exists as a second marker — when SDMA is borderline, an independent number from a different marker with different confounders is how you avoid labelling a healthy dog as kidney-diseased.

None of this makes SDMA useless. It makes it a trend tool rather than a one-shot tool — and it’s a reminder that early screening works best when you read it the way it was designed: serially, and in combination.

What Is Cystatin C?

Cystatin C is a low-molecular-weight protein produced by all nucleated cells and freely filtered at the glomerulus. Like SDMA, it’s muscle-mass-independent and rises earlier than creatinine.

Property	Cystatin C (approx.)
Normal range (dog)	0.5–1.2 mg/L
Normal range (cat)	0.6–1.8 mg/L
Rises at	~25–40% function loss
Muscle-mass dependent?	No

The important caveat: the reference interval is assay-dependent. Unlike SDMA, there’s no single universal range — different methods and labs report different numbers. Cystatin C can also be shifted by thyroid disease, glucocorticoid therapy and some inflammatory states. That’s why it’s slower to be a first-line standard, even though its physiology is solid.

Head-to-Head

Criterion	SDMA	Cystatin C
Evidence base	Strong, extensive	Moderate, growing
IRIS staging standard?	✅ Yes	❌ No
Universal reference interval?	✅ 0–14 µg/dL	❌ Assay-dependent
Muscle-mass independent	✅	✅
Rises early (~25–40% loss)	✅	✅
Confounders	Minimal	Thyroid, steroids, inflammation
Best role	First-line + staging	Confirmatory / second opinion

The honest summary: SDMA is the better first-line marker today, largely because of the IRIS staging system built around it. Cystatin C isn’t inferior — it’s less standardized. Where it shines is as an independent check when SDMA is borderline or when renal status is muddied by other disease.

IRIS Staging: Where SDMA Fits

The International Renal Interest Society (IRIS) staging system uses creatinine and SDMA together:

IRIS Stage	Dog Creatinine (mg/dL)	Cat Creatinine (mg/dL)	SDMA (µg/dL)
Stage 1	<1.4	<1.6	<18
Stage 2	1.4–2.8	1.6–2.8	18–35
Stage 3	2.9–5.0	2.9–5.0	36–54
Stage 4	>5.0	>5.0	>54

The clinical power is Stage 1: a patient with a normal creatinine but a persistently elevated SDMA is non-azotemic with reduced GFR — early CKD you can act on with diet and monitoring, and a patient you’d have missed entirely with creatinine alone.

What Early Screening Is Worth to a Clinic

This is the part that makes the difference between “interesting diagnostic” and “panel you should actually stock.”

Early CKD is one of the best ROI cases in small-animal practice because both ends work in the clinic’s favour:

The screening itself is billable. An SDMA (with creatinine) on a senior panel is a quick, high-value add — a few minutes of analyzer time, no reference-lab shipping, same-visit result.
The patient becomes a long-term relationship. A Stage 1 diagnosis is managed with renal diet, blood-pressure control and periodic re-testing — serial SDMA monitoring, not a single event. Each recheck is a billable visit.
It prevents the expensive outcome nobody profits from. A crash admission at Stage 4 is a stressful, costly, often fatal event for the owner, and a low-margin emergency for the clinic. Catching the same patient at Stage 1 converts that into years of routine, well-compensated care.

For the owner, the pitch is simple: a blood test that can catch kidney disease a year before symptoms, when a diet change still moves the needle. Most senior-cat owners take that offer.

A Practical Decision Guide

Scenario	Recommendation
Routine senior screening	SDMA (with creatinine)
Suspicious/borderline SDMA (15–17)	Recheck serially; add cystatin C to confirm
Muscle-wasted patient	SDMA or cystatin C (not creatinine alone)
Monitoring diagnosed CKD	SDMA serially (IRIS staging)
Azotemic + multiple comorbidities	SDMA for staging, cystatin C as independent check
Pre-anesthesia / pre-nephrotoxic drug	SDMA

Related products: SDMA CKD Kit · Canine Cystatin C Test · Feline Cystatin C Test

FAQ

What’s the difference between SDMA and cystatin C?

SDMA (0–14 µg/dL) is the IRIS staging standard with one universal reference range; cystatin C (~0.5–1.2 mg/L dog, 0.6–1.8 mg/L cat) varies by assay. The point isn’t which is “better” — it’s that using both is what prevents a single marker’s confounders from producing a wrong kidney diagnosis.

Why does creatinine miss early kidney disease?

Because it stays “normal” until 60–75% of function is gone — and muscle mass skews it, so a wasted senior cat can have failing kidneys and a reassuring creatinine. SDMA and cystatin C flag the decline at 25–40% loss, a year or more earlier.

Is the 14 µg/dL SDMA cut-off trustworthy?

No — 14 µg/dL is softer than marketed: independent work (McKenna 2020) found false positives in ~50% of non-azotemic dogs, and 18 µg/dL was more accurate (90% sensitivity / 83% specificity). Treat a single borderline value as a flag to recheck.

What’s the normal SDMA range for cats and dogs?

0–14 µg/dL for both. A persistent value above 14 µg/dL with a normal creatinine supports Stage 1 CKD, but a one-off 15–17 µg/dL reading should be rechecked serially.

Can cystatin C replace creatinine?

No — 2 confounders block it as a standalone: its interval is assay-dependent and it can shift with thyroid disease, steroids and inflammation. Use it alongside SDMA as a second, independent number.

Is early kidney screening worth stocking in a clinic?

Yes — 3 payoffs make it worth stocking: same-visit senior-panel revenue, long-term serial-monitoring relationships, and fewer low-margin late-stage emergencies.

Key Takeaways

Creatinine waits for 60–75% kidney loss; SDMA fires at 25–40% — that ~35-point gap is the difference between catching CKD a year early and diagnosing it at failure.
The 14 µg/dL cut-off is softer than marketed — it flags ~50% of healthy non-azotemic dogs as “early CKD” (McKenna 2020); 18 µg/dL is more accurate at 90% sensitivity / 83% specificity. This is the number the reference-lab marketing won’t lead with.
Cystatin C (0.5–1.2 mg/L dog, 0.6–1.8 mg/L cat) isn’t a backup — it’s a second opinion — two markers with different confounders are what stop a healthy dog from being labelled kidney-diseased off one borderline value.
One elevated SDMA is a re-check signal, not a diagnosis — the trend across serial readings is the actual result; a single 15–17 µg/dL means “test again,” not “kidney disease.”
The ROI isn’t the screening fee — it’s the conversion — catch CKD at 25–40% loss instead of 60–75%, and one patient becomes years of diet + monitoring visits instead of one low-margin crash admission.

References

McKenna M, et al. Clinical performance of SDMA in non-azotemic dogs. (2020) — via Cornell eClinPath SDMA review.
IDEXX. “Interpreting SDMA Test Results for Cats and Dogs.”
IRIS CKD Staging Guidelines: http://www.iris-kidney.com/guidelines/staging.html
Cornell eClinPath — SDMA: https://eclinpath.com/chemistry/kidney/sdma/
Ghys LFE, et al. “Cystatin C: A New Renal Marker.” J Vet Intern Med. 2014;28(4):1151–1164.
Hall JA, et al. “SDMA and creatinine in cats with reduced renal mass.” Am J Vet Res. 2014;75(7):589–601.

This content is for educational and product-selection purposes only. It is not a substitute for veterinary diagnosis — any animal with suspected kidney disease should be evaluated by a veterinarian. Reference ranges vary by assay; always use your analyzer’s validated intervals. Product specifications are as published by Migibio (Guangzhou Magic Biotech Co., Ltd.) and may change.